# A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

> **NCT02629289** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 153 (actual)

## Conditions studied

- Neutropenia

## Interventions

- **DRUG:** HSP-130
- **DRUG:** US-approved Neulasta
- **DRUG:** EU-approved Neulasta

## Key facts

- **NCT ID:** NCT02629289
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2016-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629289, "A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02629289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*